» Articles » PMID: 30906645

Implantable Pre-metastatic Niches for the Study of the Microenvironmental Regulation of Disseminated Human Tumour Cells

Overview
Journal Nat Biomed Eng
Publisher Springer Nature
Date 2019 Mar 26
PMID 30906645
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer survivors often carry disseminated tumour cells (DTCs), yet owing to DTC dormancy they do not relapse from treatment. Understanding how the local microenvironment regulates the transition of DTCs from a quiescent state to active proliferation could suggest new therapeutic strategies to prevent or delay the formation of metastases. Here, we show that implantable biomaterial microenvironments incorporating human stromal cells, immune cells and cancer cells can be used to examine the post-dissemination phase of the evolution of the tumour microenvironment. After subdermal implantation in mice, porous hydrogel scaffolds seeded with human bone marrow stromal cells form a vascularized niche and recruit human circulating tumour cells released from an orthotopic prostate tumour xenograft. Systemic injection of human peripheral blood mononuclear cells slowed the evolution of the active metastatic niches but did not change the rate of overt metastases, as the ensuing inflammation promoted the formation of DTC colonies. Implantable pre-metastatic niches might enable the study of DTC colonization and proliferation, and facilitate the development of effective anti-metastatic therapies.

Citing Articles

Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis.

Rad L, Hughes K, Wheeler S, Decker J, Orbach S, Galvan A Proc Natl Acad Sci U S A. 2025; 122(7):e2409852122.

PMID: 39937858 PMC: 11848328. DOI: 10.1073/pnas.2409852122.


Inflammation drives tumor growth in an immunocompetent implantable metastasis model.

Giles C, Lee J Res Sq. 2024; .

PMID: 39149496 PMC: 11326373. DOI: 10.21203/rs.3.rs-4719290/v1.


Targeting lymph nodes for enhanced cancer vaccination: From nanotechnology to tissue engineering.

Wang J, Zhang Z, Liang R, Chen W, Li Q, Xu J Mater Today Bio. 2024; 26:101068.

PMID: 38711936 PMC: 11070719. DOI: 10.1016/j.mtbio.2024.101068.


Understanding the in vivo Fate of Advanced Materials by Imaging.

Li R, Ng T, Garlin M, Weissleder R, Miller M Adv Funct Mater. 2024; 30(37).

PMID: 38545084 PMC: 10972611. DOI: 10.1002/adfm.201910369.


How much do we know about the metastatic process?.

Rodriguez-Tirado C, Sosa M Clin Exp Metastasis. 2024; 41(4):275-299.

PMID: 38520475 PMC: 11374507. DOI: 10.1007/s10585-023-10248-0.


References
1.
Yumoto K, Eber M, Wang J, Cackowski F, Decker A, Lee E . Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep. 2016; 6:36520. PMC: 5098246. DOI: 10.1038/srep36520. View

2.
Sosa M, Parikh F, Gaspar Maia A, Estrada Y, Bosch A, Bragado P . NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nat Commun. 2015; 6:6170. PMC: 4313575. DOI: 10.1038/ncomms7170. View

3.
Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

4.
Stiers P, van Gastel N, Moermans K, Stockmans I, Carmeliet G . An Ectopic Imaging Window for Intravital Imaging of Engineered Bone Tissue. JBMR Plus. 2018; 2(2):92-102. PMC: 6124161. DOI: 10.1002/jbm4.10028. View

5.
Nakahara T, Norberg S, Shalinsky D, Hu-Lowe D, McDonald D . Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006; 66(3):1434-45. DOI: 10.1158/0008-5472.CAN-05-0923. View